About Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump's cartridge rather than relying on a syringe and plunger mechanism. It also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud-based data management application that provides display therapy management data from the pump and supported blood glucose meters.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:TNDM
- CUSIP: N/A
- Web: www.tandemdiabetes.com
Capitalization:- Market Cap: $127.08 million
- Outstanding Shares: 50,228,000
Average Prices:- 50 Day Moving Avg: $5.92
- 200 Day Moving Avg: $7.52
- 52 Week Range: $2.27 - $70.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.31
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $81.51 million
- Price / Sales: 1.56
- Book Value: ($0.36) per share
- Price / Book: -7.03
Profitability:- EBITDA: ($76,170,000.00)
- Net Margins: -110.70%
- Return on Equity: -1,177.11%
- Return on Assets: -87.18%
Debt:- Debt-to-Equity Ratio: -4.09%
- Current Ratio: 2.11%
- Quick Ratio: 1.28%
Misc:- Average Volume: 1.49 million shs.
- Beta: 0.33
- Short Ratio: 3.34
Frequently Asked Questions for Tandem Diabetes Care (NASDAQ:TNDM)
What is Tandem Diabetes Care's stock symbol?
Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?
Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.
How were Tandem Diabetes Care's earnings last quarter?
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its earnings results on Thursday, July, 27th. The company reported ($4.40) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.80) by $0.40. The firm earned $21.30 million during the quarter, compared to analysts' expectations of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business's revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($6.00) earnings per share. View Tandem Diabetes Care's Earnings History.
When will Tandem Diabetes Care make its next earnings announcement?
Where is Tandem Diabetes Care's stock going? Where will Tandem Diabetes Care's stock price be in 2017?
9 brokers have issued twelve-month target prices for Tandem Diabetes Care's shares. Their predictions range from $15.00 to $90.00. On average, they expect Tandem Diabetes Care's stock price to reach $32.43 in the next year. View Analyst Ratings for Tandem Diabetes Care.
Who are some of Tandem Diabetes Care's key competitors?
Some companies that are related to Tandem Diabetes Care include Ocular Therapeutix (OCUL), SeaSpine Holdings Corporation (SPNE), T2 Biosystems (TTOO), Bioquell plc (BQE), Capnia (SLNO), Surgical Innovations Group Plc (SUN), Cytori Therapeutics (CYTX), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), Neurometrix (NURO), InspireMD (NSPR), CareFusion (CFN), Covidien Ltd (COV), CRH Medical Corp (CRHM), CRH Medical Corp (CRHM), CRH Medical Corp (CRHM), Great Basin Scientific (GBSN) and LDR Holding Corp (LDRH).
Who are Tandem Diabetes Care's key executives?
Tandem Diabetes Care's management team includes the folowing people:
- Dick P. Allen, Chairman of the Board
- Kim D. Blickenstaff, President, Chief Executive Officer, Board Member
- John Cajigas, Chief Financial Officer, Treasurer
- John F. Sheridan, Chief Operating Officer, Executive Vice President
- Brian Hansen, Chief Commercial Officer, Executive Vice President
- Susan M. Morrison, Chief Administrative Officer
- Lori Gildea, Vice President - Sales
- David B. Berger Esq., General Counsel, Corporate Secretary
- Edward L. Cahill, Independent Director
- Fred E. Cohen Ph.D. M.D., Independent Director
How do I buy Tandem Diabetes Care stock?
Shares of Tandem Diabetes Care can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tandem Diabetes Care's stock price today?
One share of Tandem Diabetes Care stock can currently be purchased for approximately $2.53.
MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Tandem Diabetes Care (NASDAQ:TNDM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.44) |
| Consensus Price Target: | $32.43 (1,181.76% upside) |
Consensus Price Target History for Tandem Diabetes Care (NASDAQ:TNDM)
Analysts' Ratings History for Tandem Diabetes Care (NASDAQ:TNDM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/10/2017 | Wedbush | Reiterated Rating | Outperform | $50.00 -> $17.00 | N/A |  |
| 10/6/2017 | Piper Jaffray Companies | Reiterated Rating | Hold | $15.00 | N/A | |
| 5/3/2017 | B. Riley | Reiterated Rating | Neutral | $15.00 | Medium | |
| 4/10/2017 | Cowen and Company | Downgrade | Outperform -> Market Perform | $15.00 | Medium | |
| 3/9/2017 | Northcoast Research | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Deutsche Bank AG | Lower Price Target | Buy | $140.00 -> $90.00 | N/A | |
| 11/2/2016 | Feltl & Co. | Downgrade | Strong-Buy -> Buy | | N/A | |
| 11/2/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $110.00 -> $40.00 | N/A | |
| 11/2/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | $150.00 -> $35.00 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Neutral | | N/A | |
| 3/24/2016 | Bank of America Corporation | Downgrade | Neutral -> Underperform | | N/A | |
| 10/21/2015 | William Blair | Reiterated Rating | Market Perform | | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Tandem Diabetes Care (NASDAQ:TNDM)Earnings History by Quarter for Tandem Diabetes Care (NASDAQ TNDM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | ($0.44) | | | | | N/A | |
| 7/27/2017 | Q2 2017 | ($4.80) | ($4.40) | $21.74 million | $21.30 million | View | N/A | |
| 4/27/2017 | Q1 2017 | ($6.60) | ($7.50) | $15.72 million | $17.50 million | View | N/A | |
| 3/8/2017 | Q4 2016 | ($6.50) | ($4.80) | $22.75 million | $24.80 million | View | Listen | |
| 7/28/2016 | Q216 | ($6.50) | ($6.00) | $23.08 million | $23.00 million | View | Listen | |
| 4/28/2016 | Q116 | ($6.90) | ($6.80) | $17.67 million | $20.06 million | View | N/A | |
| 2/24/2016 | Q415 | ($5.10) | ($4.00) | $29.17 million | $29.10 million | View | Listen | |
| 10/29/2015 | Q3 | ($8.00) | ($6.50) | $12.58 million | $15.70 million | View | Listen | |
| 7/30/2015 | Q215 | ($7.10) | ($6.50) | $14.92 million | $15.70 million | View | Listen | |
| 4/30/2015 | Q115 | ($7.90) | ($8.30) | $12.19 million | $12.30 million | View | N/A | |
| 2/24/2015 | Q414 | ($8.10) | ($7.80) | $17.16 million | $17.90 million | View | N/A | |
| 11/6/2014 | Q314 | ($8.20) | ($8.50) | $13.60 million | $13.50 million | View | N/A | |
| 7/31/2014 | Q214 | ($9.10) | ($8.30) | $10.36 million | $10.26 million | View | N/A | |
| 5/6/2014 | Q1 | ($6.90) | ($9.60) | $8.24 million | $8.10 million | View | N/A | |
| 11/8/2011 | | $2.50 | $1.80 | | | View | N/A | |
| 8/9/2011 | | $2.60 | $2.00 | | | View | N/A | |
| 5/10/2011 | | $2.40 | $2.40 | | | View | N/A | |
| 3/14/2011 | | $2.90 | $1.80 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Tandem Diabetes Care (NASDAQ:TNDM)2017 EPS Consensus Estimate: ($3.17)
2018 EPS Consensus Estimate: ($1.17)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($0.81) | ($0.62) | ($0.71) |
| Q2 2017 | 4 | ($0.63) | ($0.37) | ($0.46) |
| Q3 2017 | 4 | ($3.82) | ($0.33) | ($1.25) |
| Q4 2017 | 5 | ($2.81) | ($0.21) | ($0.76) |
| Q1 2018 | 2 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2018 | 2 | ($0.34) | ($0.28) | ($0.31) |
| Q3 2018 | 2 | ($0.28) | ($0.28) | ($0.28) |
| Q4 2018 | 2 | ($0.28) | ($0.20) | ($0.24) |
(Data provided by Zacks Investment Research)
Dividend History for Tandem Diabetes Care (NASDAQ:TNDM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tandem Diabetes Care (NASDAQ:TNDM)Insider Ownership Percentage: 20.90%
Insider Trades by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/13/2017 | Kim D Blickenstaff | CEO | Buy | 285,700 | $3.50 | $999,950.00 | |
| 3/23/2017 | Kim D Blickenstaff | CEO | Buy | 1,600,000 | $1.25 | $2,000,000.00 | |
| 8/1/2016 | John F Sheridan | EVP | Sell | 15,000 | $6.52 | $97,800.00 | |
| 5/2/2016 | John F Sheridan | COO | Sell | 2,000 | $10.61 | $21,220.00 | |
| 4/22/2016 | John F Sheridan | COO | Sell | 2,000 | $10.00 | $20,000.00 | |
| 3/7/2016 | John F Sheridan | COO | Sell | 4,000 | $10.01 | $40,040.00 | |
| 2/26/2016 | Dick Allen | Director | Buy | 10,000 | $8.24 | $82,400.00 | |
| 12/1/2015 | John F. Sheridan | COO | Sell | 2,000 | $10.14 | $20,280.00 | |
| 11/2/2015 | John F. Sheridan | COO | Sell | 4,000 | $10.00 | $40,000.00 | |
| 9/14/2015 | John F. Sheridan | COO | Sell | 2,000 | $12.51 | $25,020.00 | |
| 5/1/2015 | John F Sheridan | COO | Sell | 2,000 | $13.72 | $27,440.00 | |
| 4/1/2015 | John F Sheridan | COO | Sell | 2,000 | $12.47 | $24,940.00 | |
| 2/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.06 | $24,120.00 | |
| 1/2/2015 | John F Sheridan | COO | Sell | 2,000 | $12.75 | $25,500.00 | |
| 12/12/2014 | Dick Allen | Director | Buy | 10,000 | $11.95 | $119,500.00 | |
| 12/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.55 | $27,100.00 | |
| 11/3/2014 | John F Sheridan | COO | Sell | 2,000 | $16.00 | $32,000.00 | |
| 10/1/2014 | John F Sheridan | COO | Sell | 2,000 | $13.07 | $26,140.00 | |
| 9/2/2014 | John F Sheridan | COO | Sell | 2,000 | $13.99 | $27,980.00 | |
| 8/1/2014 | John F Sheridan | COO | Sell | 2,000 | $15.04 | $30,080.00 | |
| 7/1/2014 | John F Sheridan | COO | Sell | 2,000 | $16.42 | $32,840.00 | |
| 6/18/2014 | John F Sheridan | COO | Sell | 2,000 | $16.75 | $33,500.00 | |
| 11/13/2013 | David B Berger | General Counsel | Buy | 2,000 | $15.00 | $30,000.00 | |
| 11/13/2013 | Hlm Venture Partners Ii, L.P. | Major Shareholder | Buy | 200,000 | $15.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Tandem Diabetes Care (NASDAQ:TNDM)
Latest Headlines for Tandem Diabetes Care (NASDAQ:TNDM)
| Source: |
|
| Date | Headline |
|---|
 | Wednesday 10/18 Insider Buying Report: TNDM, ODC - Nasdaq
www.nasdaq.com - October 19 at 9:51 AM |
 | Tandem Diabetes Care, Inc. (TNDM) CEO Purchases $999,950.00 in Stock
www.americanbankingnews.com - October 17 at 7:26 PM |
 | Tandem Diabetes Care Schedules Third Quarter 2017 Earnings Press Release and Conference Call
finance.yahoo.com - October 17 at 8:12 AM |
 | Tandem Diabetes (TNDM) Prices 4.63M Share Common Offering at $3.50/Sh
www.streetinsider.com - October 15 at 7:38 AM |
 | Tandem Diabetes Care prices equity offering; shares down 31% premarket
seekingalpha.com - October 15 at 7:38 AM |
 | 7 Stocks To Watch For October 13, 2017 - Benzinga
www.benzinga.com - October 14 at 8:39 AM |
| Health Care Sector Update for 10/13/2017: TNDM,PZRX,ATRS - Nasdaq
www.nasdaq.com - October 14 at 8:39 AM |
| Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge - Benzinga
www.benzinga.com - October 14 at 8:39 AM |
| Mid-Day Market Update: Crude Oil Up Over 1%; Tandem Diabetes Care Shares Plunge
feeds.benzinga.com - October 13 at 2:16 PM |
| Tandem Diabetes Care sees ~$27M in Q3 sales; shares down 30% premarket on proposed equity offering
seekingalpha.com - October 13 at 9:22 AM |
| Tandem Diabetes (TNDM) Plans Offering of Common Stock, Series A Warrants and Series B Warrants
www.streetinsider.com - October 13 at 9:22 AM |
 | Tandem Diabetes Care (TNDM) Is Falling After Offering Announcement
www.rttnews.com - October 13 at 9:22 AM |
| Tandem Diabetes Care Announces Proposed Underwritten Public Offering of Common Stock, Series A Warrants and Series B Warrants
finance.yahoo.com - October 13 at 9:22 AM |
| Tandem Diabetes Care Announces Pricing of $16.2 Million Underwritten Public Offering of Common Stock and Warrants
finance.yahoo.com - October 13 at 9:22 AM |
| $26.07 Million in Sales Expected for Tandem Diabetes Care, Inc. (TNDM) This Quarter
www.americanbankingnews.com - October 13 at 6:44 AM |
| Q3 2017 EPS Estimates for Tandem Diabetes Care, Inc. (TNDM) Lowered by Wedbush
www.americanbankingnews.com - October 13 at 5:52 AM |
| Tandem Diabetes Care readies equity offering; shares down 23% after hours
seekingalpha.com - October 12 at 4:43 PM |
| Tandem Diabetes Care, Inc. (TNDM) Expected to Post Earnings of -$3.87 Per Share
www.americanbankingnews.com - October 11 at 12:20 PM |
| Wedbush Reaffirms Outperform Rating for Tandem Diabetes Care, Inc. (TNDM)
www.americanbankingnews.com - October 10 at 9:14 AM |
 | BRIEF-Tandem Diabetes Care shareholders approv reverse stock split
www.reuters.com - October 10 at 7:35 AM |
| BRIEF-Tandem Diabetes Care shareholders approv reverse stock split
www.reuters.com - October 10 at 7:35 AM |
| Tandem Diabetes to reverse split shares 1:10 after the close; shares off 4% premarket
seekingalpha.com - October 10 at 7:35 AM |
| Tandem Diabetes to reverse split shares 1:10 after the close; shares off 4% premarket
seekingalpha.com - October 10 at 7:35 AM |
| Tandem Diabetes Care Announces Approval of Reverse Stock Split
finance.yahoo.com - October 10 at 7:34 AM |
| Tandem Diabetes Care Announces Approval of Reverse Stock Split
finance.yahoo.com - October 10 at 7:34 AM |
| Johnson & Johnson unit exits insulin pump business amid rising competition
www.reuters.com - October 7 at 9:14 AM |
| Tandem Diabetes Care, Inc. (TNDM) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - October 6 at 9:44 PM |
| What Kind Of Risk And Return Should You Expect For Tandem Diabetes Care Inc (TNDM)?
finance.yahoo.com - October 6 at 11:30 AM |
| Tandem Diabetes Care, Inc. (TNDM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 8:52 AM |
 | Tandem Diabetes Care Reports Rapid Uptake and High Satisfaction Scores For t:slim X2 Insulin Pump Remote Software Update Following Launch of CGM Integration
www.businesswire.com - September 29 at 10:52 AM |
| Comparing Tandem Diabetes Care (TNDM) and Inogen (INGN)
www.americanbankingnews.com - September 23 at 2:32 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tandem Diabetes Care, Inc.
finance.yahoo.com - September 8 at 9:20 AM |
| Tandem Diabetes Care, Inc. (TNDM) Expected to Post Quarterly Sales of $26.07 Million
www.americanbankingnews.com - September 6 at 1:28 PM |
| Tandem Diabetes Care, Inc. (TNDM) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 8:54 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 9:55 AM |
| BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration
www.reuters.com - August 30 at 10:17 AM |
| Tandem Diabetes Care Announces FDA Approval and Launch of t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration
finance.yahoo.com - August 29 at 8:47 AM |
| Today's Research Reports on Trending Tickers: Gilead Sciences Inc. and Tandem Diabetes Care Inc.
finance.yahoo.com - August 29 at 8:46 AM |
| Tandem Diabetes Care, Inc. (TNDM) Short Interest Update
www.americanbankingnews.com - August 28 at 1:20 AM |
| Tandem Diabetes (TNDM) Granted Patent for Remote Bolus Feature on Medical Infusion Pumps
www.streetinsider.com - August 25 at 1:13 AM |
| Tandem Diabetes awarded new U.S. patent covering insulin pump; shares ahead 4% after hours
seekingalpha.com - August 24 at 8:11 PM |
| Tandem Diabetes Care Announces Issuance of Patent Related to Remote Bolus Feature for Medical Infusion Pumps
finance.yahoo.com - August 24 at 8:11 PM |
| Tandem Diabetes Care Announces Launch of t:lock Connector for its Insulin Pump Cartridges and Infusion Sets
finance.yahoo.com - August 23 at 12:39 PM |
| Critical Contrast: Exactech (EXAC) and Tandem Diabetes Care (TNDM)
www.americanbankingnews.com - August 21 at 2:24 PM |
| Tandem Diabetes Care, Inc. (TNDM) Expected to Post Quarterly Sales of $26.16 Million
www.americanbankingnews.com - August 18 at 9:42 AM |
| Tandem Diabetes Care Inc (TNDM) Expected to Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - August 16 at 4:32 PM |
| Tandem Diabetes Care Begins Enrollment in Pivotal Trial for First Touchscreen Insulin Pump with Predictive Low Glucose Suspend (PLGS)
finance.yahoo.com - August 16 at 8:17 AM |
| Invacare Corporation (IVC) versus Tandem Diabetes Care (TNDM) Financial Review
www.americanbankingnews.com - August 15 at 11:10 AM |
| ETFs with exposure to Tandem Diabetes Care, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 7:46 AM |
| Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 5:06 PM |
Tandem Diabetes Care (TNDM) Chart for Saturday, October, 21, 2017
